Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Herpesviridae Infections 1HIV Infections 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Opportunistic Infections 1

Interventions

Zidovudine 12Doxorubicin 11Vincristine 9Bleomycin 8Interferon alpha-2 6Methotrexate 5Leucovorin 5Dexamethasone 5Cyclophosphamide 5sargramostim 4Filgrastim 4Cytarabine 4Etoposide 3pomalidomide 2interferon alfa-n1 2Thalidomide 2Rituximab 2Isotretinoin 2Interleukin-2 2Didanosine 2Allopurinol 2tocilizumab 1plerixafor 1liposomal doxorubicin 1interferon gamma-1b 1abemaciclib 1Zalcitabine 1Vinblastine 1Valganciclovir 1Tumor Necrosis Factor-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Acquired Immunodeficiency Syndrome × Acyclovir × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡